Alvotech: history, ownership, mission, how it works & makes money

Born in 2013 under founder Robert Wessman with a laser focus on biosimilars, Alvotech has rapidly transformed from an Icelandic start-up into a multi-listed global player after key milestones such as FDA certification of its Reykjavik plant in 2024, the U.S. launch of Simlandi and the early-2025 roll-out of Selarsdi, European approval of AVT06 in August 2025, and a Nasdaq Stockholm listing in May 2025; the company's vertically integrated model - spanning cell line development through fill-and-finish, boosted by acquisitions like Xbrane R&D and Ivers‑Lee Group - supports nine disclosed biosimilar candidates and partnerships with Teva, STADA, Fuji, Dr. Reddy's and others to commercialize products across the U.S., Europe, Japan, China and emerging markets, driving robust financials: total revenue of $420 million for the first nine months of 2025 (up 24%), product revenue of $237 million (up 85%), adjusted EBITDA of $68 million (down 21%) with full-year guidance of $570-600 million revenue and $130-150 million adjusted EBITDA, while balance-sheet and financing moves - including SDR offerings raising ~SEK 39 million (public) and ~SEK 750 million (private), cash of $151.5 million as of June 30, 2025, and borrowings of $1,118.2 million - underscore both growth capital and leverage as Alvotech scales its mission to expand global access to affordable biologics

Alvotech (ALVO): Intro

• 2014 - Established GMP manufacturing facility in Reykjavik, Iceland.
• 2024 - Reykjavik facility received U.S. FDA certification, enabling U.S. commercial sales of its first approved product, Simlandi (adalimumab biosimilar, Humira reference).
• Early 2025 - Launched Selarsdi (ustekinumab biosimilar, Stelara reference) in both the U.S. and European markets.
• May 2025 - Listed on Nasdaq Stockholm in addition to existing listings on Nasdaq (U.S.) and Nasdaq Iceland.
• August 2025 - Achieved European approval for AVT06 (aflibercept biosimilar, Eylea reference) for ophthalmology indications.
• 2025 YTD - Reported a 24% increase in total revenues for the first nine months, reaching $420 million, driven by expanding product sales and an advancing pipeline.

• Publicly listed company with multiple exchange listings: Nasdaq (U.S.), Nasdaq Iceland, and Nasdaq Stockholm (since May 2025).
• Major investor base: institutional investors, mutual funds, and stakeholders tied to founding management (founder-led governance influence through Robert Wessman and affiliates).
• Vertically integrated structure: R&D, clinical development, and in-house commercial manufacturing based in Reykjavik to control cost, quality, and supply.

• Mission: Increase global access to biologic therapies by developing high-quality biosimilars at lower cost.
• Strategy: Focus on clinically validated, high-value biologics (immunology, oncology, ophthalmology) and pursue simultaneous filings in major markets (U.S., EU).
• Execution: Invest in proprietary process development, global regulatory filings, and selective commercial launches to capture share from originator biologics as patents expire.

• Discovery & development - Reverse-engineering reference biologics, analytical characterization, and process development to match critical quality attributes.
• Clinical - Conducts comparative clinical and immunogenicity studies required for biosimilar approvals in the U.S. and EU.
• Manufacturing - Owns and operates a FDA-certified GMP facility in Reykjavik (certified 2024) enabling in-house commercial supply.
• Regulatory strategy - Pursues parallel submissions in U.S. and EU to accelerate global launches; leverages established biosimilar regulatory pathways.
• Commercialization - Direct commercial teams and partnerships to launch products in major markets; early product rollouts include Simlandi, Selarsdi, and AVT06.

• Product sales - Revenues from commercial sales of approved biosimilars (e.g., Simlandi, Selarsdi, AVT06 upon launch/approval).
• Licensing & partnerships - Upfronts, milestones, and royalties from regional or therapeutic-area partners (where applicable).
• Manufacturing services - Potential third-party manufacturing revenue leveraging capacity in Reykjavik.
• Pipeline value realization - Milestone-driven cash inflows tied to regulatory approvals and launches of future biosimilars.

Alvotech (ALVO): History

• Listings: Nasdaq (U.S.), Iceland, Sweden - multiple venues support varying investor pools and trading liquidity.
• 2025 SDR capital raises: Two Swedish Depository Receipt offerings in 2025 generated SEK 39 million from a public offering and SEK 750 million from a private placement.
• Major transactions in 2025: Acquisition of Ivers-Lee Group (July 2025) to add assembly and packaging capabilities; appointment of Linda Jónsdóttir as CFO (July 2025), leveraging her Marel CFO/COO background.

• Strategic implications: enhanced manufacturing-to-packaging integration; deeper operational control post-Ivers-Lee acquisition.
• Financial posture: meaningful liquidity buffer ($151.5M) alongside leverage ($1,118.2M) - capital mix supports ongoing development and commercialization activities.

Alvotech (ALVO): Ownership Structure

• Founded: 2013
• Headquarters: Reykjavík, Iceland (global operations and commercial partnerships)
• Employees: ~1,300 (approximate, global workforce across R&D and manufacturing)
• Pipeline: ~11 biosimilar candidates at various clinical and regulatory stages
• Manufacturing footprint: multiple GMP suites with combined bioreactor capacity designed to support hundreds of thousands of treatment doses annually

• Mission: Expand patient access to biologic therapies by delivering affordable, high-quality biosimilars worldwide.
• Values: Purpose-driven work, scientific rigor, operational excellence, and patient-centric commercialization.
• Vertical integration: In-house cell line development, analytical labs, clinical ops, and fill/finish to reduce COGS and compress timelines.
• Commercial approach: Leverage strategic licensing and distribution partnerships to reach major markets while retaining control of manufacturing quality.

• Product development: Develop biosimilars to established biologic reference products, run comparative analytics and clinical programs, secure regulatory approvals (EMA, FDA, etc.).
• Manufacturing: Produce commercial batches in company-owned GMP facilities to lower per-dose costs and ensure supply reliability.
• Commercialization: Monetize through direct sales in select markets and through licensing/partnership agreements that provide upfront payments, milestones, and royalties.
• Revenue drivers: Product sales post-approval, milestone payments from partners, and royalties/licensing fees.

• Scale the pipeline: Continually evaluate and add biosimilar targets to expand therapeutic coverage.
• Maintain quality and cost discipline through vertical integration to be competitive on price and supply reliability.
• Foster a purpose-driven culture where employees are challenged by meaningful work aligned to patient impact.
• Pursue leadership in the biosimilar space by combining deep in-house capabilities with selective partnerships.

Alvotech (ALVO): Mission and Values

• In-house biologics development: proprietary cell-line development, analytical characterization, process development and clinical supply generation.
• Commercial-scale manufacturing: multi-product, FDA-certified biologics facility in Reykjavik, Iceland, enabling supply to the U.S. and global markets.
• Regulatory and quality functions: global regulatory submissions, pharmacovigilance and quality systems designed to meet FDA, EMA and other health authority standards.
• Strategic commercialization partnerships: Alvotech typically retains development/manufacturing control while partnering with regional commercial partners to leverage local market expertise.

• Facility status: FDA-certified for commercial biologics manufacturing, permitting supply into the U.S. market.
• Commercial readiness: multi-product capability to support clinical and commercial-scale production for multiple biosimilar programs.
• Geographic advantages: Iceland location supports EU/EEA supply and global export logistics; redundancy and scale aimed at multi-region launches.

• Teva Pharmaceuticals - commercial partnership for certain markets and product(s), including co-development/commercial rights in specified territories.
• STADA Arzneimittel AG - collaboration focused on commercializing selected biosimilars in Europe and other agreed markets.
• Fuji Pharma Co., Ltd. - regional commercialization partnership for Japan.
• Advanz Pharma - regional licensing and commercial collaboration arrangements.
• Dr. Reddy's Laboratories - distribution/commercial agreements for selected territories.

• Acquisition of Xbrane's R&D operations in Sweden - expanded biologics development capabilities and expertise in complex molecules.
• Acquisition/integration of Ivers-Lee Group (Switzerland) assets - bolstered development, regulatory and manufacturing engineering capabilities.

• Direct product sales - where Alvotech supplies finished biosimilars to partners or sells directly into markets where it retains commercial rights.
• License and commercialization agreements - upfront payments, development milestones and royalties from strategic partners that hold commercial rights in defined territories.
• Manufacturing and supply contracts - fees for commercial manufacturing and supply to partners and third parties.
• Cost-sharing/co-development - collaborative arrangements that offset development costs while securing future revenue participation.

• End-to-end control: in-house cell-line to commercial supply chain reduces COGS uncertainty and accelerates tech transfer to partners.
• Regulatory readiness: FDA-certified manufacturing supports U.S. launches and strengthens partner confidence for global supply.
• Partner-leveraged commercialization: Alvotech's model monetizes development and manufacturing strength by partnering with established regional commercial teams to scale launches faster and limit downstream sales cost exposure.

Alvotech (ALVO): How It Works

• Discovery & analytical development: demonstrating biosimilarity to originator biologics using advanced analytical, functional and non-clinical comparability studies.
• Clinical development: targeted clinical programs to establish equivalence or non-inferiority in key endpoints for each biosimilar.
• Manufacturing: vertically integrated GMP manufacturing to control quality, cost and supply continuity.
• Regulatory strategy: coordinated submissions to EMA, FDA, PMDA (Japan) and other regulators to enable multi-region approvals.
• Commercialization: direct launches in some territories and partner-based launches (licensing/commercial agreements) in others to scale distribution rapidly.

• Product sales: direct revenue from commercial sales of launched biosimilars in the U.S., Europe, Japan, Canada and other markets.
• Licensing & partnership income: upfront fees, development and regulatory milestones, and ongoing sales royalties from commercial partners in defined territories.
• Service and manufacturing revenue: contract manufacturing and related services where applicable.

• Geographic mix: revenue growth is tied to rapid uptake in high-value markets (U.S., EU, Japan, Canada) where biosimilars displace originator biologics.
• Partner strategy: licensing deals accelerate market access and provide non-dilutive cash via upfronts, milestones and royalties while mitigating commercial execution risk in specific territories.
• Manufacturing scale: owning GMP facilities reduces COGS per unit as volumes increase, improving margins long term.
• Pipeline & launches: near-term revenue sensitivity to timing of approvals and launches of targeted biosimilars; AVT02 and AVT04 are current primary commercial drivers.

Alvotech (ALVO): How It Makes Money

• Core revenue streams: product sales of approved biosimilars, licensing & commercialization fees from global partners, milestone & royalty income from collaboration agreements, and contract manufacturing for select third parties.
• Vertical integration drives margin expansion: in‑house clinical, analytical and manufacturing capabilities reduce COGS and shorten time‑to‑market versus outsourcing models.
• Commercial strategy: direct launches in select markets combined with regional partners (distribution and co‑promotion) to accelerate uptake and reduce commercial capex.

• How products convert to cash:
  • Direct sales - marketed either by Alvotech or in co‑promotion with partners; revenue recognized as product sales.
  • Licensing & supply agreements - upfront and milestone payments at development and regulatory milestones; ongoing supply/revenue from manufacture.
  • Royalties - percentage of net sales from partner‑commercialized products.
  • Manufacturing contracts - fee‑for‑service income from third‑party biologics production where applicable.

• Market position: Alvotech occupies a strong niche in the global biosimilars market with a diversified pipeline and a strategy to commercialize both directly and via partners, targeting high‑value biologics whose originator patents have expired or are expiring.
• Milestones achieved: regulatory approvals and commercial launches in major regions, strategic acquisitions/asset purchases to broaden portfolio and strengthen manufacturing capacity, and execution of partnership deals that provide near‑term revenue visibility.
• Financial trajectory: revenue growth driven by new product launches and incremental partner revenue; operating leverage expected as fixed manufacturing costs are absorbed by increasing commercial volumes.
• Competitive advantages:
  • Vertically integrated platform reduces per‑unit COGS and shortens development timelines.
  • Multiple candidates across therapeutic areas hedge single‑product risk.
  • Strategic partnerships help rapid market penetration and de‑risk commercialization spend.
• Outlook drivers: approvals of additional biosimilars, expansion of commercial footprint (U.S., EU and selected international markets), successful execution of supply agreements, and continued realization of milestone and royalty streams.
• Risks to monitor: pricing pressure in biosimilars, patent litigation on reference products, speed of payer adoption, and manufacturing scale‑up risks.